Logo image of RZLV

REZOLVE AI LTD (RZLV) Stock Fundamental Analysis

NASDAQ:RZLV - Nasdaq - GB00BQH8G337 - Common Stock - Currency: USD

2.43  -0.12 (-4.71%)

Fundamental Rating

0

Overall RZLV gets a fundamental rating of 0 out of 10. We evaluated RZLV against 283 industry peers in the Software industry. Both the profitability and financial health of RZLV have multiple concerns. RZLV does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year RZLV has reported negative net income.
In the past year RZLV has reported a negative cash flow from operations.
RZLV Yearly Net Income VS EBIT VS OCF VS FCFRZLV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 -1M -2M -3M -4M

1.2 Ratios

RZLV has a worse Return On Assets (-1118.56%) than 99.27% of its industry peers.
Industry RankSector Rank
ROA -1118.56%
ROE N/A
ROIC N/A
ROA(3y)-1.32%
ROA(5y)N/A
ROE(3y)-1.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RZLV Yearly ROA, ROE, ROICRZLV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 -2 -4 -6 -8 -10

1.3 Margins

RZLV has a worse Gross Margin (55.56%) than 66.18% of its industry peers.
The Profit Margin and Operating Margin are not available for RZLV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 55.56%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RZLV Yearly Profit, Operating, Gross MarginsRZLV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023

More info and screens

0

2. Health

2.1 Basic Checks

The number of shares outstanding for RZLV has been reduced compared to 1 year ago.
Compared to 1 year ago, RZLV has a worse debt to assets ratio.
RZLV Yearly Shares OutstandingRZLV Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 5M 10M 15M 20M
RZLV Yearly Total Debt VS Total AssetsRZLV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -117.78, we must say that RZLV is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -117.78, RZLV is doing worse than 97.45% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -117.78
ROIC/WACCN/A
WACCN/A
RZLV Yearly LT Debt VS Equity VS FCFRZLV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 0.02 indicates that RZLV may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.02, RZLV is doing worse than 99.64% of the companies in the same industry.
RZLV has a Quick Ratio of 0.02. This is a bad value and indicates that RZLV is not financially healthy enough and could expect problems in meeting its short term obligations.
RZLV has a Quick ratio of 0.02. This is amonst the worse of the industry: RZLV underperforms 99.64% of its industry peers.
Industry RankSector Rank
Current Ratio 0.02
Quick Ratio 0.02
RZLV Yearly Current Assets VS Current LiabilitesRZLV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2M 4M 6M 8M

More info and screens

0

3. Growth

3.1 Past

RZLV shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1783.05%.
EPS 1Y (TTM)-1783.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-24.32%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, RZLV will show a very negative growth in Earnings Per Share. The EPS will decrease by -62.44% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-170.05%
EPS Next 2Y-128.68%
EPS Next 3Y-62.44%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RZLV Yearly Revenue VS EstimatesRZLV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M
RZLV Yearly EPS VS EstimatesRZLV Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 -0.05 -0.1 -0.15 -0.2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RZLV. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RZLV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RZLV Price Earnings VS Forward Price EarningsRZLV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RZLV Per share dataRZLV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3

4.3 Compensation for Growth

A cheap valuation may be justified as RZLV's earnings are expected to decrease with -62.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-128.68%
EPS Next 3Y-62.44%

More info and screens

0

5. Dividend

5.1 Amount

RZLV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REZOLVE AI LTD

NASDAQ:RZLV (2/24/2025, 9:49:09 AM)

2.43

-0.12 (-4.71%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners1.16%
Inst Owner ChangeN/A
Ins Owners56.79%
Ins Owner ChangeN/A
Market Cap436.87M
Analysts81.82
Price Target6.12 (151.85%)
Short Float %11.03%
Short Ratio0.23
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-47.18%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2201.39
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.38
EYN/A
EPS(NY)-0.21
Fwd EYN/A
FCF(TTM)-0.11
FCFYN/A
OCF(TTM)-0.09
OCFYN/A
SpS0
BVpS-0.35
TBVpS-0.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1118.56%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 55.56%
FCFM N/A
ROA(3y)-1.32%
ROA(5y)N/A
ROE(3y)-1.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.02
Quick Ratio 0.02
Altman-Z -117.78
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)258.51%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1783.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-24.32%
EPS Next Y-170.05%
EPS Next 2Y-128.68%
EPS Next 3Y-62.44%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1272.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-317.14%
EBIT Next 3Y76.12%
EBIT Next 5YN/A
FCF growth 1Y-1772.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1472.41%
OCF growth 3YN/A
OCF growth 5YN/A